Board
Alison Lawton
Independent Chair
Alison Lawton
Independent Chair
Alison Lawton is an executive leader with over 35 years of experience in the biopharma industry. She was president and CEO of Kaleido Biosciences (KLDO) where she led its IPO, and prior to that chief operating officer of Aura Biosciences (AURA). Ms. Lawton spent more than 20 years in various positions of increasing responsibility at Genzyme, and subsequently at Sanofi (following the acquisition of Genzyme by Sanofi in 2011) including as General Manager of Genzyme Biosurgery (a ~$1Billion annual revenue business) and as senior vice president of Global Market Access & Regulatory Affairs for Genzyme.
Alison currently serves as Chair of the Board of Directors for Dianthus Therapeutics (DNTH); as an independent director for ProQR Therapeutics (PRQR) and BlueRock Therapeutics. She previously served as Chair of the board for Magenta Therapeutics (MGTA), and as a non-executive director of Aeglea (AGLE), Kaleido Biosciences (KLDO), Verastem (VSTM), CoLucid (CLCD) until its acquisition by Eli Lilly, and Cubist Pharmaceuticals (CBST) until its acquisition by Merck & Co. She was Chair of the Board of the Regulatory Affairs Professional Society and the industry representative on the FDA Cell and Gene Therapy Advisory Committee.
Michael Anstey, PhD
Non-Executive Director
Michael Anstey, PhD
Non-Executive Director
Michael is a Partner at Cambridge Innovation Capital specialising in life sciences and health care investments.
Before joining CIC he was a Principal in the Health Care Practice Area at The Boston Consulting Group. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan.
Prior to BCG, Michael was an Investment Analyst at Oxford Capital Partners.
Michael was also co-founder of an early-stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease.
Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford.
Michael manages CIC's investments in Bicycle Therapeutics (NASDAQ: BCYC), Epitopea, TRIMTech Therapeutics, Immutrin, Nuclera, and Congenica. He is also a co-founder of Innovate Cambridge, a initiative developing an ambitious and inclusive innovation strategy for Greater Cambridge, with the goal of ensuring it remains the leading innovation ecosystem in Europe.
Laurence Barker, MBA PhD
Non-Executive Director
Laurence Barker, MBA PhD
Non-Executive Director
Laurence is a Partner at SV Health Investors focussed on the Dementia Discovery Fund (DDF).
With over 20 years of venture, biotech and pharma experience, Laurence has supported the funding and formation of numerous DDF companies developing transformational new medicines for dementia. He joined SV in 2016 having played an active role in setting up the DDF.
Prior to SV, Laurence was Head of Investment Management in Worldwide Business Development at GSK where he was responsible for managing GSK’s venture investment portfolio and led licensing transactions for the pharma R&D business. Prior to GSK, Laurence worked in business development at several biotech companies.
Marie-Claire Peakman, MRPharmS PhD
Non-Executive Director
Marie-Claire Peakman, MRPharmS PhD
Non-Executive Director
Marie-Claire is a Partner at Pfizer Ventures and Executive Director, Worldwide Business Development. Marie-Claire is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Curve Therapeutics, DEM Biopharma, Grey Wolf Therapeutics and Mozart Therapeutics, She is an observer on the boards for Capstan Therapeutics, Crossbow Therapeutics, Mediar Therapeutics and TRex Bio.
Marie-Claire brings 25 years of scientific leadership at Pfizer, delivering small molecule therapeutics to the clinic and to market across multiple therapeutic areas. Most recently she led the Primary Pharmacology Group which she founded in 2009 and which played key roles in the identification of Paxlovid™ (nirmatrelvir), Cibinqo™ (abrocitinib), Litfulo™ (ritlecitinib) and multiple other small molecules currently in the clinic. She has additional experience leading compound management, high throughput ADME, data support and management, genetically modified models, bioimaging and biobanking. Prior to Pfizer Marie-Claire gained experience at The Wellcome Foundation, at Guy’s Hospital, London, UK and held postdoctoral positions at Yale University. She is a member of the advisory board for Connecticut Bioscience Innovation Fund and has multiple roles on non-profit boards in the community.
Marie-Claire received a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She is a member of the Royal Pharmaceutical Society.
Jeffrey Moore, MBA DPhil
Non-Executive Director
Jeffrey Moore, MBA DPhil
Non-Executive Director
Jeff is President of MP Healthcare Venture Management (MPH), the VC firm of Mitsubishi Tanabe Pharma Corporation, and Board of Director member of Diamond Edge Ventures (DEV), the VC arm of Mitsubishi Chemical Group. Previously, Jeff was a Kauffman Fellow with the early stage venture firm Research Corporation Technologies. He has held various business and scientific roles at Millennium Pharmaceuticals and Scriptgen Therapeutics.
Jeff received his DPhil from the University of Oxford, studying virus vaccines, and did postdoctoral training in infectious disease at Harvard Medical School. Dr. Moore received his MBA as a Sloan Fellow at MIT, and his BSc in Biology from the University of New Brunswick.
Previously, he led MPH’s investments in Covagen, F-Star, QurAlis, Genocea, Korro Bio, and miRagen, and currently is a Board member or Observer at Blacksmith Medicines, M34/Capsigen, Draupnir, Outrun, PharmEnable, Ribometrix, SOLA Bio, Sonde Health and TRIMTECH.
Hakan Goker, PhD
Non-Executive Director
Hakan Goker, PhD
Non-Executive Director
Hakan is Managing Director of M Ventures and heads the Biotechnology Investments covering Healthcare and Life Sciences Tools and Technologies.
Hakan has been investing in the sector since 2006 and joined M Ventures in 2013. Previously, Hakan was a partner at Aescap Venture investing in European opportunities. Hakan started his investment career at Atlas Venture focusing on global investment opportunities in healthcare and medical technologies across US, Europe and Asia. He was instrumental in the creation and financing, business and R&D strategies of multiple companies in their formation years including Bicycle, Nimbus Discovery, and f-Star while at Aescap and Atlas. Hakan continues his active investing role and represents M Ventures on multiple portfolio companies.
He comes from an academic background receiving his PhD in oncology from the Institute of Cancer Research/ University of London, UK and continuing his scientific career with post doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his B.Sc. Hons, from University College London. Hakan is based in Amsterdam at the M Ventures head office.
Nicki Thompson, PhD
CEO
Nicki Thompson, PhD
CEO
Nicki has over 25yrs’ leadership experience in pharma and biotech.
Nicki was founding CEO of Amphista Therapeutics, a targeted protein degradation company, where she steered Amphista through Series A and B funding rounds, raising ~$150Million in funding and closing two pharma collaborations (deal value $2.3Bn).
Her previous roles include: VP/Global Head of External Drug Discovery (Roche); Senior Director, Business Development (GSK).
Nicki’s Biotech experience includes Chairperson of Nanna Therapeutic’s Board , founding CEO at VirionHealth and Head of Drug Discovery at Syntaxin.
© TRIMTECH Therapeutics
TRIMTAC, TRIMVEC and TRIMGLUE are registered trademarks of TRIMTECH Therapeutics Ltd.
